ZEJULA (niraparib) Extends PARP Inhibitor
Therapy to More Women1

EXPLORE WHAT ZEJULA CAN OFFER PATIENTS WITH OVARIAN CANCER
IN THE FOLLOWING INDICATIONS1:


ZEJULA is the only once-daily oral
PARP inhibitor monotherapy for ovarian cancer1-3